

Fujifilm India enhances disease management & prognosis of Covid-19

17 September 2020 | News

FUJI DRI-CHEM brings healthcare professionals a new world of clinical chemistry

FUJIFILM

Fujifilm India Private Limited, a pioneer in imaging and healthcare technologies, in line with its commitment to provide aid for the unprecedented crisis, has been strengthening its pledge to contribute to healthcare experts with the help of its progressive Dri Chemistry solutions that can aid LDH and CRP testing in just 6 minutes.

Recent research suggests that relatively high levels of LDH alone seem to play a crucial role in distinguishing the vast majority of cases that require immediate medical attention. This finding is consistent with current medical knowledge that high LDH levels are associated with tissue breakdown occurring in various diseases, including pulmonary disorders such as pneumonia. The use of the biomarkers suggests a simple and operable decision rule to quickly predict patients at the highest risk, allowing them to be prioritized and potentially reducing the mortality rate.

With Fujifilm's dry chemistry analyzer, healthcare professionals can perform multiple test parameters of Clinical Chemistry. It has a built-in auto-pipetting system, requires no calibration and no water, providing easy preparation and maintenance. The new FUJI DRI-CHEM NX500i and NX700i deliver results using a simple 3-step procedure. With its quick, easy operation and compactness, 'Real Time and Borderless' Clinical Chemistry has now been made possible.

The clinical chemistry solutions deliver fine chemical technology which is Japanese patented technology for the manufacturing of Dri Chemistry Slides. Further, with plug and play equipment, the NX500i can run up to 128 tests per hour and the NX700i can run upto 190 tests per hour respectively.